February 11, 2008 – DiaMedica Inc. (TSX-V:DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce positive pre-clinical data for DM-99, its third clinical drug candidate. Results demonstrated, with statistical significance, greater glucose metabolism in normal animals treated with DM-99 when compared to untreated animals.The study was conducted in the Wasserman Laboratory at the Diabetes Research and Training Center at Vanderbilt University in Nashville, Tennessee. In the study, the amount of glucose being metabolized was measured using the well established hyperinsulinemic euglycemic clamp model. Specifically, animals treated with DM-99 were able to use 41% more glucose than an untreated animal (p<0.04) during the first sixty minutes of the study...
DiaMedica's Press Release
